Skip to main
DWTX

DWTX Stock Forecast & Price Target

DWTX Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Dogwood Therapeutics is a promising investment opportunity due to its strong focus on addressing unmet medical needs in chronic neuropathic pain and neuropathy. The company has a diverse product pipeline with potential milestones and partnerships in the near future, including the initiation of SP16 clinical trials in 3Q26 and discussions with potential partners for legacy assets and development partnerships for Halneuron, which could lead to significant upside for the stock. Additionally, the company has a solid financial position with a projected 12-month price target of $12.00 per share, derived from a risk-adjusted net present value analysis of $429M, supported by expected revenues through 2033.

Bears say

Dogwood Therapeutics is facing numerous financial challenges, including a lack of revenue, pre-clinical stages of development, and a reliance on licensing agreements for funding and commercialization. Despite the potential of their pipeline, the recent licensing of their anti-viral assets to PridCor presents minimal short-term impact and the lack of upfront payments or near-term clinical milestones creates uncertainties for future financial stability. The company's focus on Halneuron overshadows the potential of their anti-viral assets, which may lead to missed opportunities for revenue and growth in the long-term.

DWTX has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Dogwood Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Dogwood Therapeutics, Inc. (DWTX) Forecast

Analysts have given DWTX a Strong Buy based on their latest research and market trends.

According to 1 analysts, DWTX has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $12, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $12, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Dogwood Therapeutics, Inc. (DWTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.